Saudi Journal of Medicine and Public Health

https://saudijmph.com/index.php/pub

https://doi.org/10.64483/jmph-194

Interdisciplinary Perspectives on Preterm Labor: Clinical Management, Epidemiological Trends, and Emergency Nursing Interventions in Maternal Health

Mousa Ali Mousa Ayashi [(1)] , Rashid Marde Bakhet AlDosari [(2)] , Mashael Abdullah Refaie [(3)] , Mousa Ali Mousa Ayashi [(1)] , Faisal Lafi Al-Mutairi [(4)] , Mohammed Ali Mohammed Awaf [(5)] , Ahmed Ali Awaf [(6)] , Mohammed Ali Mohammed Awaf [(7)] , Hamad Ibrahim Hamad Alghareeb [(8)] , Nemah Ahmed Rajhi [(9)] , Sumayyah Saud Tuaysan Alanazi [(10)]

(1) Al-Hurrath General Hospital, Ministry of Health, Saudi Arabia,
(2) Alsulayyil General Hospital, Ministry of Health, Saudi Arabia,
(3) Ministry Of Health, Saudi Arabia,
(4) Third District, Wathilan General Hospital, Ministry of Health, Saudi Arabia,
(5) Environmental Health Department, Jazan Health Cluster, Ministry of Health, Saudi Arabia,
(6) Samta General Hospital , Jazan Health Cluster, Ministry of Health, Saudi Arabia,
(7) Environmental Health Unit , Jazan Health Cluster, Ministry of Health, Saudi Arabia,
(8) Okaz Primary Healthcare Center, Ministry of Health, Saudi Arabia,
(9) Al Hair Haelth Centre, Ministry of Health, Saudi Arabia,
(10) Ministry Of Health Branch Office, Saudi Arabia

Abstract

Background: Preterm labor (PTL), defined as regular uterine contractions with cervical change between 20 and 37 weeks' gestation, is a leading cause of neonatal morbidity and mortality worldwide. It is a complex syndrome driven by multiple etiologies, including infection, inflammation, uterine overdistension, and vascular pathology.

Aim: This article synthesizes interdisciplinary perspectives on PTL, aiming to clarify its definition, pathophysiology, and evidence-based management. It emphasizes a risk-stratified approach to diagnosis and treatment to optimize neonatal outcomes while avoiding unnecessary interventions.

Methods: A comprehensive review is presented, covering the epidemiology, multifactorial pathophysiology, and clinical evaluation of PTL. Diagnostic methods include history, physical exam, transvaginal ultrasound for cervical length, and biomarkers like fetal fibronectin. Management strategies are analyzed, focusing on the gestational age-based application of antenatal corticosteroids, tocolysis, magnesium sulfate for neuroprotection, and Group B Streptococcus prophylaxis.

Results: Accurate diagnosis remains challenging, as most symptomatic patients do not deliver imminently. Risk stratification using cervical length and biomarker testing is crucial. Time-sensitive interventions, particularly antenatal corticosteroids and magnesium sulfate, significantly improve neonatal outcomes when appropriately targeted to high-risk patients between 24 and 34 weeks gestation.

Conclusion: Effective management of PTL requires an integrated, interdisciplinary approach. Mastery of diagnostic criteria, risk stratification, and the timely administration of evidence-based therapies is essential to reduce the global burden of prematurity.

Keywords: Preterm Labor, Preterm Birth, Neonatal Outcomes, Antenatal Corticosteroids, Magnesium Sulfate, Risk Stratification.

1. Introduction

Preterm labor (PTL) is classically defined as the onset of regular uterine contractions accompanied by cervical change occurring between 20 0/7 and 36 6/7 weeks of estimated gestational age (EGA), a window during which the fetus remains at heightened vulnerability to complications of prematurity [1]. Contemporary diagnostic frameworks emphasize not only the presence of contractions but also objective cervical findings. The American College of Obstetricians and Gynecologists (ACOG) allows diagnosis when regular contractions are accompanied by cervical dilation of ≥ 2 cm prior to 37 weeks EGA, whereas international guidance from the World Association of Perinatal Medicine and the Perinatal Medicine Foundation (WAPM–PMF) advocates a ≥ 3 cm threshold to classify spontaneous preterm labor (sPTL), reflecting efforts to improve specificity and reduce overdiagnosis in symptomatic patients who will otherwise proceed to term [1][2]. This distinction is clinically consequential because management strategies, disposition, and the anticipated timeline to delivery differ depending on the likelihood of imminent preterm birth (PTB) [1][2]. Physiologically,

*Corresponding author e-mail: Mayashy@Moh.Gov.Sa (Mousa Ali Mousa Ayashi).

Receive Date: 25 September 2025, Revise Date: 25 October 2025, Accept Date: 29 October 2025

sPTL represents a final common pathway triggered by heterogeneous etiologies—decidual hemorrhage, subclinical infection/inflammation, uterine overdistension, cervical insufficiency, and maternal-fetal stress signaling—culminating in premature activation of the myometrium, cervical remodeling, and membrane weakening. Once cervical dilation reaches ≥ 3 cm, the probability of spontaneous resolution declines substantially, a practical inflection point that often heralds progression to delivery despite conservative measures [2]. Nevertheless, therapeutic intervention may benefit selected high-risk patients who have not yet reached this dilation threshold—particularly those with a short cervix, positive biochemical markers, or concomitant risk factors—by extending pregnancy long enough to administer antenatal corticosteroids and magnesium sulfate for neuroprotection, and to facilitate transfer to an appropriate level of neonatal care [1][2][3].

A key clinical challenge is that the majority of individuals who present with symptoms suggestive of sPTL—such as regular contractions, pelvic pressure, or low back pain—will ultimately deliver at term, underscoring the centrality of risk stratification to avoid unnecessary interventions and hospitalization [3]. Triage therefore prioritizes distinguishing true labor from false labor and identifying those at highest risk for imminent PTB. Multimodal assessment incorporates digital or speculum examination for cervical change, transvaginal ultrasound to measure cervical length, and selective use of biochemical testing such as fetal fibronectin (fFN) in appropriately screened populations. Integrating this data with the gestational age informs a tiered approach to care: outpatient observation for low-risk presentations versus targeted in-hospital management for those at substantial risk of early delivery [3]. The clinical stakes of sPTL are considerable because PTB—particularly at earlier gestations—drives much of perinatal morbidity and mortality. Spontaneous PTL with intact membranes accounts for approximately 40% to 45% of all preterm births, a burden that persists across health systems and contributes disproportionately to neonatal respiratory distress syndrome, intraventricular hemorrhage, necrotizing enterocolitis, sepsis, long-term neurodevelopmental impairment, and extended neonatal intensive care utilization [4][5][6][7]. Risk is strongly modulated by gestational age at delivery, with extremely preterm birth (< 28 weeks) associated with the highest complication rates. Consequently, accurate and timely diagnosis of sPTL serves as the gateway to evidence-based interventions that meaningfully alter neonatal trajectory, including antenatal corticosteroids to accelerate fetal lung maturity, magnesium sulfate for fetal neuroprotection prior to early PTB, and judicious tocolysis to gain a short therapeutic window for these treatments to take effect [4][5][6][7]. Management principles therefore revolve around two tasks: (1) establishing the probability of imminent delivery and (2) deploying time-sensitive therapies and logistics proportional to that risk. When presentation occurs remote from term, clinicians weigh the maternal-fetal risks and benefits of short-course tocolysis—recognizing that tocolytics do not prevent preterm delivery but can defer it for 48–72 hours—against contraindications such as chorioamnionitis, fetal compromise, or advanced labor. In parallel, antenatal corticosteroids are administered to reduce neonatal respiratory and neurological morbidity, while magnesium sulfate before anticipated early PTB reduces the risk of cerebral palsy. Where appropriate, group B Streptococcus prophylaxis, maternal transport to tertiary centers, and consultation with neonatology are coordinated to optimize outcomes [1][3][4].



Figure-1: Causes of preterm labour.

Because many symptomatic patients will proceed to term, stewardship is required to minimize iatrogenesis. Overuse of tocolysis, unnecessary hospitalization, or indiscriminate transfer can impose costs and risks without improving outcomes. Here, the divergence between a ≥ 2 cm versus ≥ 3 cm cervical dilation threshold illustrates the balance between sensitivity and specificity: lower thresholds capture more true cases but may overtreat those unlikely to deliver imminently, while higher thresholds enrich for patients in whom aggressive management and tertiary-level resources are most justified [1][2][3]. Institutions increasingly deploy standardized algorithms that combine cervical length cutoffs with fFN results to tailor decisions on admission, treatment, and observation, thereby aligning practice with the probabilistic nature of sPTL and the heterogeneous risk of PTB [3][4][5]. Finally, the public health context cannot be ignored. PTB remains a leading cause of neonatal death and long-term disability worldwide, with sPTL representing a sizeable, potentially modifiable fraction of the burden [4][5][6][7]. Health system strategies—universal or targeted cervical length screening, progesterone use for selecting high-risk populations, smoking cessation, infection surveillance, and addressing social determinants—operate upstream from acute triage and complement bedside decision-making. Yet even with prevention, the need for precise diagnosis and rapid, coordinated management of sPTL will persist. Accordingly, the introduction frames this review's aims: to clarify definitional thresholds, synthesize a risk-stratified diagnostic approach, and outline interventions that maximize neonatal benefit while minimizing maternal and system-level harms. In sum, sPTL is both common and consequential; mastering its evaluation and management is essential to reducing the global burden of prematurity and improving short- and long-term neonatal outcomes [1][2][3][4][5][6][7].

Etiology:

The etiology of spontaneous preterm labor (sPTL) is multifactorial and represents a complex interplay between maternal, fetal, placental, and environmental factors. Rather than being a single disease entity, sPTL is a final common pathway resulting from diverse pathophysiological processes that culminate in premature activation of the labor cascade. Central to its development are mechanisms involving decidual inflammation, decidual hemorrhage, pathologic uterine distention, and conditions that impose physiologic stress on the fetus or mother, each of which can trigger a cascade of biochemical and mechanical events leading to cervical effacement, uterine contractions, and membrane rupture [7][8][9][10][11].

Decidual Inflammation and Infection

Infection and inflammation are among the most consistently implicated causes of sPTL. Ascending bacterial infection from the lower genital tract can invade the choriodecidual interface, leading to chorioamnionitis and activation of inflammatory mediators. Pathogens such as *Ureaplasma urealyticum*, *Mycoplasma hominis*, and *Gardnerella vaginalis* are commonly associated with intrauterine infection. The host immune response involves upregulation of pro-inflammatory cytokines—interleukin (IL)-1β, IL-6, and tumor necrosis factor-alpha (TNF-α)—and prostaglandins, which promote uterine contractility and cervical ripening. Inflammatory stimulation of matrix metalloproteinases also weakens fetal membranes, predisposing to preterm prelabor rupture of membranes (PPROM). Even subclinical infection can suffice to initiate this cascade. Thus, the intrauterine inflammatory pathway accounts for a substantial proportion of spontaneous preterm births, particularly those occurring before 32 weeks' gestation [7][8][9].

Decidual Hemorrhage and Placental Pathology

Another major etiologic mechanism is decidual hemorrhage, which encompasses placental abruption and other causes of retroplacental bleeding. Hemorrhage at the maternal–fetal interface activates thrombin generation, which in turn stimulates uterine contractions and cervical change through direct myometrial action and secondary prostaglandin production. Placental abruption, chronic intervillous bleeding, and disorders such as placenta previa can therefore precipitate premature labor. These processes frequently overlap with maternal vascular pathology, including uteroplacental insufficiency related to chronic hypertension, diabetes, and autoimmune disease, which compromise placental perfusion and integrity. Fetal hypoxia and oxidative stress arising from these conditions may further activate the hypothalamic–pituitary–adrenal (HPA) axis, increasing fetal cortisol and contributing to preterm initiation of the labor cascade [9][10][11].

Pathologic Uterine Distention

Uterine overdistention represents a mechanical and biochemical trigger of sPTL, particularly in the context of multifetal gestation or abnormal amniotic fluid volume (polyhydramnios). Stretch-induced signaling activates myometrial gap junction formation and oxytocin receptor expression, while mechanical stretching of the chorion and amnion promotes release of prostaglandins and inflammatory mediators. These processes mimic those observed at term but occur prematurely when the uterus is excessively distended. Conversely, oligohydramnios can signify placental insufficiency and fetal compromise, both of which contribute to preterm activation of parturition pathways. Structural anomalies such as uterine septa or fibroids may also alter uterine compliance, predisposing to early contractility [8][10].

Maternal–Fetal Stress and Endocrine Activation

Chronic or acute maternal stress, whether physical, psychological, or environmental, is increasingly recognized as an important etiologic contributor. Activation of the maternal and fetal HPA axes leads to increased secretion of corticotropin-releasing hormone (CRH) from the placenta, cortisol from the adrenal glands, and downstream prostaglandin synthesis, all of which promote myometrial activity and cervical ripening. Stress may be induced by systemic illnesses (e.g., hypertensive disorders, infections), undernutrition, or psychosocial hardship. Likewise, fetal stress—manifested by growth restriction or hypoxemia—stimulates CRH and cortisol production as an adaptive mechanism that inadvertently accelerates labor onset [7][8][11].

Major Risk Factors

Epidemiological studies have identified multiple risk factors that reflect the convergence of these pathophysiologic pathways. The history of prior preterm birth remains one of the strongest predictors of recurrence, suggesting a shared underlying predisposition, whether anatomical (short cervix), inflammatory, or genetic. Shortened cervical length, as assessed by transvaginal ultrasound (<25 mm before 24 weeks), is a well-validated marker of susceptibility to spontaneous labor. Infections—whether intrauterine, urinary, or vaginal (e.g., bacterial vaginosis)—are recognized modifiable risk factors whose treatment can reduce recurrence in certain populations [5][7][12]. Placental pathologies such as placental abruption and placenta previa directly contribute through bleeding and inflammatory activation, while multifetal gestation increases both mechanical and hormonal stress. Disorders of amniotic fluid—either polyhydramnios or oligohydramnios—and conditions characterized by uteroplacental insufficiency, such as chronic hypertension, preeclampsia, diabetes mellitus, and autoimmune diseases, amplify risk through compromised oxygenation and inflammatory or thrombotic changes. Evidence of fetal growth restriction, abnormal umbilical artery Doppler velocimetry, and oligohydramnios all point to chronic placental dysfunction and signal elevated likelihood of sPTL [9][10][11].

Sociodemographic and behavioral determinants further shape risk. Studies consistently demonstrate that Black race is associated with higher rates of preterm birth independent of socioeconomic status, implicating complex interactions among genetics, chronic stress, systemic inequities, and access to care. Extremes of maternal age, particularly mothers aged 40 years or older, are similarly linked with adverse outcomes, possibly due to cumulative vascular and metabolic comorbidities. Nutritional factors—poor diet, low maternal body mass index (BMI), and micronutrient deficiencies—can impair placental development and increase vulnerability to infection and inflammation. Conversely, obesity may predispose to preeclampsia and gestational diabetes, conditions associated with medically indicated preterm delivery. Inadequate prenatal care delays identification and management of modifiable risks, while substance use, including tobacco, alcohol, and illicit drugs, directly contributes to uteroplacental dysfunction and fetal hypoxia, intensifying the likelihood of preterm labor [5][7][12].

Multifactorial Nature and Interactions

Crucially, these etiologies rarely act in isolation. Many patients exhibit overlapping mechanisms—for instance, a hypertensive patient with placental insufficiency and subclinical infection or a twin pregnancy complicated by polyhydramnios and cervical shortening. Genetic predispositions, epigenetic modifications, and environmental stressors further modulate susceptibility. The complexity underscores the need for individualized risk assessment integrating obstetric history, cervical metrics, infection screening, and social determinants. Modern research increasingly focuses on biomarker discovery (e.g., proteomic and metabolomic profiling of amniotic and cervical fluids) to elucidate the molecular networks linking inflammation, endocrine activation, and extracellular matrix remodeling. In essence, spontaneous preterm labor arises from diverse yet interrelated biological pathways—infectious, vascular, mechanical, and neuroendocrine—that prematurely trigger the processes of parturition. Understanding these mechanisms and the associated risk factors is pivotal for early identification of at-risk pregnancies and the design of preventive interventions, such as progesterone supplementation, cervical cerclage, infection screening, and lifestyle modification. By addressing both the biological and social underpinnings of sPTL, clinicians can move closer to mitigating the global burden of preterm birth and its profound consequences for neonatal survival and long-term health [7][8][9][10][11][12].

Epidemiology

Preterm labor (PTL) and preterm birth (PTB) remain among the most pressing global challenges in obstetric and perinatal health. Despite major advances in prenatal care, neonatal medicine, and social health interventions, the burden of preterm birth persists, contributing significantly to neonatal morbidity, mortality, and long-term disability worldwide. Epidemiologic data highlight that only a small subset of women who present with symptoms of spontaneous preterm labor (sPTL) will deliver imminently. Studies demonstrate that only about 5.5% of symptomatic patients deliver within one week of presentation, and even among those who meet clinical diagnostic criteria for sPTL, fewer than 10% will give birth within seven days [1][3]. These figures illustrate the diagnostic and predictive challenges associated with sPTL, emphasizing the importance of distinguishing true labor from false labor to prevent unnecessary interventions and hospitalization [3]. Globally, the incidence of preterm birth is estimated at approximately 10% of all live births, accounting for nearly 15 million preterm infants each year. Of these, 40% to 45% are attributed to spontaneous preterm labor with intact membranes, while the remainder are medically indicated due to maternal or fetal complications such as preeclampsia, placental abruption, or intrauterine growth restriction [7][13]. The burden of PTB, however, is not evenly distributed across regions or populations. Rates tend to be higher in low- and middle-resource settings, where access to prenatal care, infection screening, and emergency obstetric services is limited. These disparities underscore the intersection of biological, socioeconomic, and healthcare system factors that shape preterm birth outcomes worldwide [13].

Racial and ethnic disparities in preterm birth are particularly well-documented in high-resource countries. Data from a large retrospective study conducted within the Kaiser Permanente health system in California between 2009 and 2020 revealed statistically significant differences in the incidence of spontaneous preterm birth by race [14]. The study found that non-Hispanic Black individuals had an incidence of sPTB of 5.5%, compared to 3.6% among non-Hispanic White individuals ($P < 0.001$), highlighting a persistent racial gap despite similar access to healthcare services. These findings align with national surveillance data in the United States and similar trends in other developed nations, suggesting that structural and social determinants—such as chronic stress, systemic inequities, environmental exposures, and differential access to high-quality prenatal care—contribute substantially to risk variation beyond biological predisposition. In summary, while the global incidence of PTB remains steady at around one in ten births, the underlying causes and contributing factors vary widely by geography, socioeconomic status, and ethnicity. The relatively low proportion of symptomatic women who deliver within a week underscores the diagnostic complexity of sPTL and the need for better predictive tools, such as cervical length measurement and biochemical markers. Addressing disparities through equitable access to prenatal care, infection prevention, and social support interventions remains critical for reducing the overall global burden of preterm birth and improving maternal and neonatal outcomes [1][3][7][13][14].

Pathophysiology

The pathophysiology of spontaneous preterm labor (sPTL) is intricate and multifactorial, representing the premature activation of physiological pathways that normally culminate in term parturition. Labor, whether at term or preterm, is the result of a coordinated sequence of events involving decidual activation, fetal membrane signaling, myometrial contractility, and cervical remodeling. In sPTL, these processes are initiated abnormally early by a diverse array of pathologic stimuli, including intrauterine infection, decidual hemorrhage, uterine overdistension, maternal or fetal stress, and breakdown of maternal-fetal immune tolerance [7][8]. Although the initiating factors differ, the downstream biochemical cascades converge on shared molecular pathways that ultimately produce uterine contractions, cervical effacement and dilation, and in some cases, preterm rupture of membranes.

Decidual and Membrane Activation

Labor begins with activation of the decidua (maternal uterine lining) and fetal membranes (chorion and amnion), a process that represents the interface between maternal and fetal systems. Normally, this activation occurs near term as part of physiologic maturation; however, in preterm labor, it can occur prematurely due to pathological triggers. Intrauterine infection or inflammation is one of the most common mechanisms implicated in this premature activation. When microorganisms ascend from the vagina into the uterine cavity, they colonize the decidua, chorion, and amnion, initiating a localized immune response.

Bacterial components—such as lipopolysaccharides (LPS) from Gram-negative bacteria—bind to toll-like receptors (TLRs) expressed on the cervix, placenta, and fetal membranes. This interaction triggers a powerful inflammatory response characterized by activation of nuclear factor-kappa B (NF-κB) and the release of pro-inflammatory cytokines, including interleukin-1β (IL-1β), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6). These cytokines upregulate the synthesis of prostaglandins (particularly prostaglandin E2 and F2α) within the decidua and fetal membranes, leading to uterine contractility. Simultaneously, these mediators induce matrix metalloproteinases (MMPs), enzymes that degrade the extracellular matrix (ECM) of the cervix and fetal membranes [15]. The combined effect of enhanced prostaglandin production and ECM degradation results in progressive cervical softening, dilation, and increased membrane fragility—key hallmarks of the labor process. Within the cervix, inflammatory cell infiltration into the cervical stroma amplifies these effects. Neutrophils, macrophages, and T cells release additional cytokines and prostaglandins, accelerating collagen remodeling and altering the balance of glycosaminoglycans that maintain cervical integrity. This localized breakdown of cervical structure leads to premature cervical dilation and facilitates the rupture of fetal membranes. Clinically, the degree of ECM disruption can be indirectly evaluated by measuring fetal fibronectin (fFN) levels in cervicovaginal secretions; the presence of fFN reflects detachment of the chorionic membranes from the decidua and is a predictive biomarker for impending preterm delivery [15].

Sterile Inflammation and Immune Dysregulation

Not all cases of sPTL involve overt infection. In many patients with intact membranes, the initiating insult is sterile inflammation, driven by abnormal activation of the maternal and fetal immune systems. This phenomenon is characterized by elevated concentrations of cytokines, chemokines, and inflammatory mediators in the amniotic fluid, even in the absence of identifiable microorganisms [16]. Triggers may include decidual necrosis, oxidative stress, or damage-associated molecular patterns (DAMPs) released from apoptotic cells or degraded tissue. These endogenous molecules activate the same pattern-recognition receptors (such as TLRs and NOD-like receptors) that respond to infection, leading to inflammation that mimics the microbial response. In sterile inflammatory sPTL, elevated IL-6 and IL-8 levels promote leukocyte infiltration, prostaglandin release, and cervical remodeling similar to that observed in infection-associated cases. Although the initiating mechanisms differ, the final common pathway—characterized by prostaglandin synthesis, MMP activation, and myometrial excitability—produces indistinguishable clinical outcomes. These parallel underscores the unifying concept of preterm parturition as a syndrome of multiple etiologies converging on shared effector pathways [8][16].

Decidual Hemorrhage and Vascular Malperfusion

Another major contributor to preterm labor is maternal vascular malperfusion of the placenta, often secondary to decidual hemorrhage or placental abruption. In this scenario, bleeding at the maternal-fetal interface exposes decidual tissue to thrombin, a potent uterotonic agent. Thrombin stimulates the myometrium directly and indirectly through upregulation of prostaglandin synthesis and increased intracellular calcium in smooth muscle cells. Concurrently, ischemic injury from placental underperfusion releases free radicals and inflammatory mediators that further activate the decidua and membranes. The resulting inflammatory-thrombotic milieu disrupts local hemostasis and tissue integrity, promoting uterine contractility and cervical change [7][8].

Uterine Overdistension and Mechanical Pathways

Mechanical stress represents another pathway leading to sPTL, especially in multifetal gestations, polyhydramnios, or uterine anomalies. Uterine stretch induces mechanical signaling within the myometrium and fetal membranes, stimulating the expression of contraction-associated proteins such as connexin-43 and oxytocin receptors. These facilitate gap-junction formation between myometrial cells, allowing for synchronized uterine contractions. Simultaneously, overdistension enhances prostaglandin synthesis and local inflammation, creating a self-reinforcing cycle of uterine activation. Animal models and human data confirm that mechanical stress alone can initiate the molecular cascades typically associated with infection or endocrine activation, highlighting its independent contribution to premature labor onset [8].

Endocrine and Neuroendocrine Mechanisms

The maternal-fetal endocrine system also plays a central role in the initiation of labor. Under conditions of maternal or fetal stress, the hypothalamic-pituitary-adrenal (HPA) axis is activated, leading to increased production of corticotropin-releasing hormone (CRH) from the placenta. CRH, in turn, stimulates adrenocorticotropic hormone (ACTH) release and cortisol production in both the mother and fetus. Elevated cortisol levels exert a positive feedback effect on placental CRH synthesis, amplifying the response. Placental CRH also directly induces prostaglandin synthesis in the decidua and amniochorion, further promoting myometrial contractility and cervical ripening [7]. This endocrine cascade converges with mechanical and inflammatory pathways to produce functional progesterone withdrawal—a shift in the balance of progesterone receptor isoforms that reduces progesterone's quiescent effect on the myometrium. As a result, the uterus becomes increasingly responsive to contractile stimuli such as prostaglandins and oxytocin, leading to coordinated contractions. Oxytocin, secreted from the posterior pituitary gland, reinforces this process by stimulating myometrial calcium influx and promoting rhythmic, powerful contractions that characterize active labor. In summary, the pathophysiology of spontaneous preterm labor encompasses an intricate network of interacting biological systems—infectious, inflammatory, vascular, mechanical, and endocrine. Whether triggered by bacteria, sterile inflammation, hemorrhage, or stress, these stimuli converge on a common terminal pathway involving prostaglandin production, ECM degradation, and myometrial activation. Understanding these mechanisms not only elucidates why sPTL is challenging to predict and prevent but also informs targeted therapeutic strategies, such as infection control, anti-inflammatory interventions, tocolysis, and hormonal modulation. Ultimately, dissecting the molecular underpinnings of sPTL is essential for improving diagnostic accuracy, optimizing management, and mitigating the global burden of preterm birth [7][8][15][16].

History and Physical

Preterm labor (PTL) remains a clinical diagnosis that synthesizes symptoms with objective cervical findings. According to ACOG, PTL is "generally based on clinical criteria of regular uterine contractions accompanied by a change in cervical dilation, effacement, or both, or initial presentation with regular contractions and cervical dilation of at least 2 cm," a definition that underscores the primacy of demonstrable cervical change over uterine activity alone [1]. The literature has variably defined "regular contractions" from four to twelve per hour, reflecting heterogeneous study designs and clinical settings; ACOG does not mandate a numeric threshold, emphasizing instead the combination of contraction pattern with cervical dynamics [2]. By contrast, the WAPM–PMF joint guideline offers operational specificity, recommending a threshold of six or more contractions per 30 minutes and advising observation for at least two hours to document contraction frequency and cervical evolution before confirming the diagnosis of spontaneous PTL (sPTL) [1][2]. This two-hour window is particularly useful in emergency and triage environments, where premature labeling of false labor can lead to unnecessary interventions, hospitalization, or transfer.



Figure-2: Signs and Symptoms of preterm labour.

History

Patients with sPTL typically report menstrual-like cramping, rhythmic uterine tightening, pelvic pressure, or low back pain that waxes and wanes in concert with contractions. A careful history should characterize the duration, frequency, regularity, and intensity of contractions and document whether they are increasing in strength or clustering—a trajectory that correlates with higher likelihood of cervical change. Although frequent, regular, and strong contractions occurring every two to three minutes often presage progressive dilation, sPTL can still occur with less dramatic patterns, so clinicians should not exclude the diagnosis solely on contraction phenotype [1][2]. Associated symptoms—an increase in mucoid vaginal discharge, light bleeding or spotting, or a subjective sense of "pelvic pressure"—may reflect cervical effacement and dilation. Review of the antenatal record is essential, as prior obstetric complications, cerclage placement, or a history of preterm birth refine pretest probability and guide immediate next steps. Eliciting risk factors and symptoms that point toward a specific etiology further anchors decision-making. A sudden gush or persistent leakage of clear fluid suggests preterm premature rupture of membranes and should prompt focused evaluation for membrane integrity. Fever, uterine tenderness, or foul-smelling discharge heighten concern for intrauterine infection or chorioamnionitis, mechanisms that activate inflammatory pathways implicated in sPTL. Vaginal bleeding with abdominal pain raises suspicion for placental abruption, whereas painless bleeding in late pregnancy is consistent with placenta previa—both placental disorders that increase the risk of preterm labor. A detailed social and medical history identifies modifiable and contextual risk factors, including substance use, nutritional status, adequacy of prenatal care, and extremes of maternal age, while comorbidities such as chronic hypertension, diabetes, or autoimmune disease signal potential uteroplacental insufficiency and a lower threshold for progression to preterm birth [1][2].

Physical Examination

The physical examination begins with maternal vital signs and global assessment, followed by systematic abdominal and pelvic evaluation. In stable patients, a speculum examination should precede any digital cervical assessment. This sequencing avoids iatrogenic alteration of vaginal secretion tests and mitigates infectious risk if membranes are ruptured. On abdominal examination, clinicians often palpate contractions as circumferential tightening of the gravid uterus; the uterus is usually nontender in uncomplicated labor. Diffuse or focal uterine tenderness, particularly when accompanied by fever or maternal tachycardia, suggests inflammatory or hemorrhagic processes that warrant targeted investigation. Fetal lie, presentation, and an estimated fetal weight should be documented to contextualize management options if delivery appears imminent. The speculum examination provides crucial information on cervical appearance, degree of dilation and effacement visible at the external os, membrane status, and the presence of blood or abnormal discharge. Pooling of straw-colored fluid in the posterior fornix or leakage from the cervical os supports a diagnosis of ruptured membranes; when visual inspection is equivocal, standard bedside tests for membrane rupture should be employed to avoid misclassification. Blood in the vaginal vault can reflect placental abruption or, less commonly, placenta previa; however, minor bleeding may also occur with progressive cervical dilation. Malodorous or purulent discharge should prompt collection of samples for microbiologic testing, given the established association between infection, inflammation, and sPTL [1][2]. After placenta previa and membrane rupture have been reasonably excluded—by chart review, recent imaging, or bedside ultrasound—a digital cervical examination is appropriate to quantify dilation, effacement, and fetal station. Careful technique minimizes discomfort and avoids inadvertent membrane disruption. Findings of advanced dilation are highly prognostic; cervical dilatation of at least 3 cm prior to 34 weeks' gestation is strongly associated with preterm delivery, guiding the urgency of antenatal corticosteroids, magnesium sulfate for neuroprotection, group B Streptococcus prophylaxis when indicated, and potential maternal transfer to a higher level of care [1][2]. If the placental location is unknown, a quick transabdominal ultrasound should precede any digital exam to avoid provoking hemorrhage in an undiagnosed previa.

Continuous cardiotocographic monitoring refined the clinical picture by correlating patient-reported symptoms with objectively recorded contraction patterns while simultaneously assessing fetal well-being. Documentation should include contraction frequency, regularity, and duration over the observation period recommended by WAPM–PMF, recognizing that a subset of symptomatic patients will not demonstrate progressive cervical change over two hours and can be safely discharged with return precautions and follow-up [1][2]. Fetal heart rate baseline, variability, and the presence or absence of decelerations inform the safety of expectant management versus the need for expedited intervention should nonreassuring patterns emerge. In sum, the history and physical examination in suspected PTL hinge on methodical, staged information gathering careful symptom characterization; targeted inquiry into risk factors and red-flag features for PPROM, infection, or placental pathology; and a structured examination that prioritizes speculum assessment before digital evaluation. Alignment with consensus definitions—ACOG's emphasis on cervical change with contractions and WAPM–PMF's operational thresholds and observation period—helps standardize diagnosis across care settings while reducing both under- and over-treatment. This disciplined approach ensures that patients at genuine risk of imminent preterm birth are identified swiftly and receive time-sensitive therapies, and that those likely to continue to term are spared unnecessary interventions and hospitalization [1][2].

Evaluation

Beyond history and bedside examination, the evaluation of a patient with threatened preterm labor (PTL) aims to 1) confirm or exclude ruptured membranes, 2) identify infectious or inflammatory contributors, 3) stratify short-term risk of spontaneous preterm birth (sPTB), and 4) gather anatomic data that guide management and delivery planning. In practice, this entails targeted laboratory testing, judicious use of cervicovaginal biomarkers, and both transvaginal and limited obstetric ultrasounds, with the understanding that some tools are most informative in the early–moderate preterm period and are less helpful at late preterm gestational ages [17][18]. Because test performance depends heavily on sampling technique and sequence, clinicians should prioritize specimen collection (e.g., fetal fibronectin) before digital cervical examination to avoid false positives and loss of diagnostic clarity [27]. A first, nonnegotiable step is determining membrane status, as management diverges sharply when preterm premature rupture of membranes (PPROM) is present. When rupture is not obvious on speculum examination, a structured diagnostic approach is recommended. Microscopy for ferning, vaginal pH testing, and a suite of commercial immunoassays detecting amniotic fluid proteins—most notably placental alpha microglobulin-1 (PAMG-1) and insulin-like growth factor binding protein-1 (IGFBP-1)—substantially improve diagnostic accuracy in equivocal cases [19][20][21][22][23]. Establishing whether membranes are intact not only refines risk estimation for near-term delivery but also directs decisions about antibiotics, corticosteroids, and the suitability of tocolysis [17][18].

Simultaneously, clinicians should address infection screening, both to uncover treatable precipitants of sPTL and to inform intrapartum care if labor progresses. Rectovaginal group B Streptococcus (GBS) culture should be obtained at presentation unless a culture within the previous five weeks is already available or another indication for intrapartum prophylaxis exists (e.g., documented GBS bacteriuria this pregnancy or a prior neonate with invasive GBS disease) [24]. Because lower urinary tract infection (UTI) and asymptomatic bacteriuria are linked to increased sPTB risk—and because dysuria, frequency, and suprapubic discomfort can mimic contraction-related symptoms—urine culture with or without urinalysis is indicated in the PTL workup [17][18]. In patients with risk factors not recently screened, testing for sexually transmitted infections (chlamydia, gonorrhea, syphilis) is appropriate, given their association with inflammatory pathways that drive cervical remodeling and uterine activity [17][18]. A urine drug screen may be considered selectively when risk factors are present or when placental abruption is suspected as a cause of sPTL; results can guide counseling and, if necessary, multidisciplinary support [17][18]. Imaging complements laboratory assessment by clarifying both anatomy and immediate obstetric concerns. Transvaginal ultrasound (TVUS) is the reference method for cervical length measurement and is most informative prior to 34 weeks' EGA. A normal cervical length typically ranges from 35 to 48 mm; an abnormally short cervix confers increased risk of sPTB in both singleton and multifetal gestations, with the shortest lengths portending the highest risk [17][25]. Many studies employ a 25 mm threshold in symptomatic patients, below which the likelihood of delivery increases meaningfully, whereas a cervical length ≥30 mm is associated with a <5% risk of sPTB in the short term, supporting outpatient management when other concerning features are absent [17][26]. TVUS should be performed with standardized technique to avoid overestimation (e.g., empty bladder, minimal probe pressure, three consistent measurements), as small errors can shift risk categorization.

A limited obstetric ultrasound augments evaluation by confirming fetal presentation, estimating amniotic fluid volume (both a fetal well-being marker and, when abnormal, a risk factor for sPTL), and providing an estimated fetal weight (EFW) [17][18]. These data prepare the perinatal team for potential neonatal resuscitation needs, guide counseling on prognostic expectations if delivery is imminent, and, if malpresentation is identified, inform decisions about route of delivery should advance labor supervene. Among cervicovaginal biomarkers, fetal fibronectin (fFN) is the most widely used adjunct in symptomatic patients with indeterminate cervical length. fFN is an extracellular matrix (ECM) glycoprotein at the decidual–chorionic interface; its detection in cervicovaginal secretions reflects ECM disruption—a process often shared by pathways that precipitate sPTL [27]. The principal strength of fFN testing is its negative predictive value: a negative fFN result is associated with a low probability of delivery within 7 days, which supports conservative management and may prevent unnecessary hospitalization [28]. By contrast, a positive fFN increases risk but has limited positive predictive value on its own, curbing its usefulness as a stand-alone trigger for intervention [17][29][30]. Test performance is highly technique-sensitive: digital cervical exams, vaginal bleeding, or recent intercourse can cause false positives; therefore, the swab should be collected before any internal manipulation when possible [27].

Clinical integration of fFN with cervical length enhances accuracy. Patients with cervical length 20–30 mm and positive fFN constitute a high-risk cohort for delivery within 7 days and warrant escalated monitoring and timely administration of antenatal corticosteroids and magnesium sulfate as indicated [17][29]. Qualitative fFN assays are typically positive at ≥50 ng/mL, while quantitative fFN testing—where available—reveals a dose-response relationship between concentration and risk. In a prospective study, raising the positivity threshold from 50 ng/mL to 500 ng/mL increased the positive predictive value from 32% to 75% for sPTB within 14 days, demonstrating how higher cutoffs enrich for those most likely to deliver imminently [31]. Unfortunately, quantitative assays are not universally accessible, including in parts of the United States, limiting routine use [31]. Beyond fFN, ROM biomarkers also provide prognostic information in patients with intact membranes. In a prospective study of >400 symptomatic patients with cervical lengths 15–30 mm, both PAMG-1 and IGFBP-1 tests showed negative predictive values ~97% for sPTB within 7 days, but PAMG-1 displayed a markedly higher positive predictive value (61%) compared with IGFBP-1 (28%) [32]. While these assays are primarily validated for diagnosing membrane rupture, such data support their adjunctive risk-stratification value in selected clinical contexts [32]. As with fFN, results should be interpreted in light of sampling conditions, concomitant bleeding, and recent exams to avoid misclassification.



Figure-3: Pathogenesis of preterm labour.

Two practical caveats deserve emphasis. First, gestational age matters: both cervical length and fFN are most helpful in the early to moderate preterm window; at late preterm ages, their discriminative value wanes as many patients would be managed expectantly regardless of test results [17][18]. Second, no single test is determinative. Optimal decision-making integrates maternal vitals, contraction patterns over an appropriate observation period, membrane status, infection screens, cervical length, and biomarker results—balanced against institutional resources and patient preferences—to tailor disposition and therapy [1][2][17][18]. In summary, a high-quality evaluation of threatened PTL is systematic and sequenced: confirm or exclude PPROM with speculum exam and validated assays; obtain GBS culture, urine studies, and targeted STI testing to identify treatable precipitants; acquire TVUS cervical length and a limited obstetric ultrasound to contextualize risk and delivery planning; and use fFN (preferably before any digital exam) selectively when cervical length is intermediate or indeterminate. When combined thoughtfully, these data sharpen short-term risk estimation, avert unnecessary admissions for low-risk patients, and, for those likely to deliver soon, enable timely corticosteroids, magnesium sulfate, and maternal transfer—interventions that demonstrably improve neonatal outcomes [17][18][24][26][28][31][32].

Treatment / Management

Management of spontaneous preterm labor (sPTL) is fundamentally risk-stratified and time-sensitive. Decisions hinge on estimated gestational age (EGA) at presentation, the presence and pattern of uterine activity, cervical dilation and its trajectory, membrane status, and, in selected scenarios, transvaginal cervical length with or without fetal fibronectin (fFN) testing. In practical terms, patients with threatened preterm labor are considered high risk of sPTB within 7 days if any of the following are present: regular contractions with cervical dilation ≥3 cm; regular contractions with documented cervical change over time; symptoms of sPTL plus a short cervix (<15–20 mm) irrespective of fFN; symptoms plus an intermediate cervix (15–30 mm) and positive fFN; or ruptured membranes. Once high-risk status is established, interventions are tailored by gestational strata and may include antenatal corticosteroids, a 48-hour course of tocolysis to afford steroids maximal efficacy, magnesium sulfate for neuroprotection, and group B Streptococcus (GBS) prophylaxis. When membranes are ruptured, latency antibiotics are indicated and managed separately. Equally important, every effort should be made to ensure delivery occurs at a facility capable of supporting preterm neonates, including access to neonatal intensive care services and subspecialty personnel [33].

Gestational Age–Based Approach

Although many institutions summarize care in tabular pathways, the core elements can be narrated succinctly. For 22 to 31 6/7 weeks, patients at high risk of sPTB should receive antenatal corticosteroids and magnesium sulfate for neuroprotection; tocolysis is typically appropriate in the absence of contraindications (with agents such as indomethacin, nifedipine, magnesium sulfate, or terbutaline used according to institutional protocols), and GBS prophylaxis is indicated when status is unknown or positive. Between 32 and 33 6/7 weeks, corticosteroids remain indicated; tocolysis generally favors nifedipine (or terbutaline where appropriate), while magnesium sulfate for neuroprotection is not routinely used but may be considered in certain guideline frameworks as discussed below; GBS prophylaxis continues as above. For 34 to 36 6/7 weeks, professional recommendations vary; consideration of corticosteroids is guideline-dependent, tocolysis is not recommended, magnesium sulfate is not used for neuroprotection, and GBS prophylaxis is provided if status is unknown or positive. These strata align care intensity with gestational-age–dependent neonatal benefit and maternal risk [33].



Figure-4: Management of preterm labour.

Antenatal Corticosteroids

Antenatal corticosteroids improve neonatal outcomes when administered to individuals at high risk of PTB, with the greatest benefit realized when delivery occurs 48 hours to 7 days after dosing [2]. Accordingly, corticosteroids are universally recommended from viability through 34 weeks EGA, and ACOG/SMFM/WAPM-PMF suggest individualized use in the periviable period down to 22 0/7 weeks when neonatal resuscitation is planned [2]. Beyond 34 weeks, recommendations diverge across organizations (see below), reflecting evolving evidence and differing valuations of benefits versus risks (A1). The ALPS trial (2016) randomized 2831 patients with singleton gestations at 34–36 6/7 weeks and high risk of birth within 7 days (and no prior steroids) to betamethasone versus placebo. Betamethasone reduced neonatal respiratory morbidity overall; however, secondary analyses suggested that patients with sPTL or PPROM had lower baseline respiratory complication rates than those with indicated PTB, irrespective of steroid exposure, during the late preterm window [34][35]. A notable trade-off is increased neonatal hypoglycemia with late-preterm steroid use [34]. Longer-term neurodevelopmental and metabolic outcomes remain uncertain; a 2022 meta-analysis (>1.25 million children) found a slight increase in neurocognitive/behavioral diagnoses by age 1 among late-preterm births (adjusted hazard ratio [aHR] 1.12, 95% CI 1.05–1.20) and an elevated aHR 1.47 (95% CI 1.36–1.60) among term births exposed in utero, though confounding and indication bias complicate inference [36].

Against this backdrop, major organizations have issued nuanced guidance. WAPM-PMF recommends individualized treatment and suggests a 34 0/7-week cutoff for use [2]. SMFM advises counseling and offering a single course to patients who meet ALPS inclusion (singleton 34–36 6/7 weeks), but recommends against late-preterm steroids in pregestational diabetes because of neonatal hypoglycemia risk [37]. ACOG supports SMFM and also recommends against steroids when intraamniotic infection is present [38]. NICE NG25 suggests considering steroids from 34 to 35 6/7 weeks; RCOG Green-Top 74 recommends offering steroids up to 34 6/7 weeks [39]; SOGC advises consideration at 34–36 6/7 weeks [40]; and WHO recommends steroids 24–34 weeks (including PPROM, multifetal gestations, hypertensive disorders, or growth restriction), advising against use in chorioamnionitis and in planned cesarean at 34–36 6/7 weeks [41]. When used, employ one of two standard regimens: betamethasone 12 mg IM ×2 doses 24 h apart or dexamethasone 6 mg IM ×4 doses 12 h apart [1][2] (A1). ACOG and WHO consider a single repeat "rescue" course in patients who remain at high risk ≥7–14 days after an initial course; evidence supports either a full 48-hour repeat course or a single dose of betamethasone after prior standard therapy [42].

Tocolysis

Tocolytics transiently reduce the frequency and intensity of uterine contractions and may briefly prolong pregnancy, creating a 48-hour window to complete antenatal steroids, transfer care, or treat a reversible trigger [43]. They do not address the underlying drivers of sPTL, do not reliably delay birth to term, and do not independently improve neonatal outcomes; moreover, they carry maternal and fetal side-effect profiles [44]. Consequently, use should be limited to 48 hours and reserved for patients who stand to benefit from a short delay—e.g., to finish steroids or to allow safe transport [1] (A1). Tocolysis is generally recommended from viability through 34 weeks; in the periviable period, decisions are individualized, and in high-resource settings may be considered down to 22 0/7 weeks when resuscitation is planned [1][2]. Reassess promptly if contractions persist despite therapy, seeking evidence of infection, fetal compromise, abruption, progressive dilation, or membrane rupture. Contraindications include preeclampsia with severe features, intraamniotic infection, significant antepartum hemorrhage, fetal demise or lethal anomaly, and substantial maternal cardiac disease; in PPROM, tocolysis can be appropriate when no infection is present [1][2]. Three classes have the strongest evidence base: calcium channel blockers (CCBs), cyclooxygenase (COX) inhibitors, and β2-agonists [1]. Other options include oxytocin receptor antagonists (atosiban), magnesium sulfate, and nitric oxide donors (nitroglycerin); combination tocolysis is generally not recommended [2] (A1). CCBs (nifedipine). By preventing intracellular calcium mobilization, CCBs reduce myometrial contractility. Nifedipine has a favorable safety profile and is frequently first line, particularly after 30–32 weeks. ACOG recommends nifedipine as first line at 32–33 6/7 weeks; WHO, NICE, and WAPM-PMF recommend it from 24–33 6/7 weeks [1][2][41]. A common regimen is 20 mg PO loading, then 10 mg PO every 6 h [1][2][41]. Maternal side effects reflect peripheral vasodilation (dizziness, flushing, palpitations, tachycardia, nausea); avoid in hypotension and preload-dependent cardiac states. Adverse fetal effects have not been significant [1].

COX inhibitors (indomethacin). COX inhibitors suppress prostaglandin synthesis, attenuating contractions. Many experts prefer indomethacin before 32 weeks based on a large meta-analysis of 58 randomized trials showing superior efficacy and tolerability as first-line therapy; a 2022 systematic review supported these findings [44][47]. The inflammatory underpinnings of many sPTL cases may explain this advantage. Nonetheless, exposure beyond 48 hours increases risks of ductus arteriosus constriction and oligohydramnios, predominantly in the third trimester. Reversible ductal narrowing has been detected in ~50% after a mean 5.1 days of therapy around 31 weeks; marked increases occur at ~32 weeks, prompting limitation to short courses and earlier gestational ages [48][53]. In the second trimester, prolonged indomethacin carries much lower rates of ductal constriction (~6.5%) [49]. Older studies suggested increased risks of severe intraventricular hemorrhage, necrotizing enterocolitis, and periventricular leukomalacia with indomethacin tocolysis, without differences in PDA, RDS, BPD, sepsis, or mortality; these data require cautious interpretation given heterogeneity in exposure windows and cointerventions [50]. β2-agonists (terbutaline). Although they relax smooth muscle and can acutely suppress contractions, tachyphylaxis limits durability and maternal adverse effects are more frequent (tachycardia, tremor, hyperglycemia, hypokalemia). They are generally second line behind CCBs and COX inhibitors; NICE recommends against their use for tocolysis [47][51]. Because β2-agonists raise heart rate and glycemia, they are relatively contraindicated in significant tachyarrhythmias, ischemic-sensitive cardiac disease, and poorly controlled diabetes; diabetics require close glucose and potassium monitoring and may need insulin infusion if used [1].

Oxytocin receptor antagonists (atosiban). Widely used in Europe and unavailable in the U.S., atosiban is an acceptable first-line alternative to nifedipine in WAPM-PMF guidance [2]. A randomized trial (n = 510) comparing oral nifedipine to IV atosiban found no difference in the proportion pregnant at 48 h or in composite perinatal outcomes. Atosiban has few maternal side effects beyond infusion-site reactions and no absolute contraindications apart from allergy [52]. Magnesium sulfate (as a tocolytic). Magnesium is as effective as other agents in delaying sPTB but is generally second line due to a higher potential for serious maternal adverse events [43][44]. Its unique value lies in neuroprotection; it is often given for that indication in early sPTL and can simultaneously serve as the tocolytic of record. If contractions persist despite magnesium for neuroprotection, ACOG allows adding a second tocolytic; indomethacin is commonly chosen. Do not combine magnesium with CCBs or β2-agonists, given synergistic smooth-muscle relaxation and risk of respiratory depression [1]. Nitric oxide donors (nitroglycerin). Evidence does not support routine use. A 2014 Cochrane review concluded there is insufficient evidence to recommend nitric oxide donors for threatened PTL [53] (A1).

Magnesium Sulfate for Neuroprotection

Administered within 24 hours of early preterm birth, magnesium sulfate reduces the risk of cerebral palsy and likely reduces severe IVH, with the strongest evidence at earlier gestations [54][55][56]. A 2024 Cochrane review reaffirmed benefit before 34 weeks EGA [55]. Guideline thresholds vary: WHO strongly recommends magnesium for women at imminent risk before 32 weeks; ACOG (reaffirmed 2020) states the evidence is strongest before 32 weeks and recommends local protocols; NICE recommends offering it 24–29 6/7 weeks and considering it 30–33 6/7 weeks; WAPM-PMF recommends use up to 31 6/7 weeks and considering up to 33 6/7 weeks when the fetus is <5th percentile for weight [1][2][55][57]. Contraindications include myasthenia gravis; use caution in neuromuscular disease and heart block. Because magnesium is renally excreted, dose-adjust in renal dysfunction and monitor for toxicity with serial vitals, urine output, deep tendon reflexes, and cardiopulmonary assessments. With appropriate monitoring in high-resource settings, the 2024 Cochrane review found no increase in maternal death or cardiac/respiratory arrest versus placebo [55].

GBS Prophylaxis

Administer GBS intrapartum prophylaxis according to standard recommendations. Preterm delivery itself is a risk factor for early-onset GBS disease and is an indication for prophylaxis when GBS status is unknown. RCOG recommends intrapartum prophylaxis in all preterm patients [58].

Intrapartum and Postpartum Care

Continuous cardiotocography during sPTL monitors fetal well-being and contraction dynamics. Continue GBS prophylaxis and magnesium for neuroprotection through delivery as indicated. Postnatally, delayed cord clamping benefits preterm neonates—improving initial hematocrit, diastolic pressure, and blood volume and reducing resuscitation, transfusion, and death before discharge [59][60][61]. A 2023 randomized trial (n = 204) supports 30–60 seconds as safe and effective, whereas

120 seconds was associated with increased polycythemia and longer phototherapy durations [62].

Resolution of sPTL and Disposition

Many cases of threatened PTL are resolved spontaneously. After 34 weeks, patients with intact membranes and reassuring fetal testing can often be discharged with close follow-up and clear return precautions. Before 34 weeks, disposition is individualized, incorporating gestational age, cervical status, obstetric history, co-morbidities, distance from the hospital, and patient preference. Routine bed rest is not recommended; at home, patients may maintain typical daily activities, though recreational exercise and heavy lifting should be avoided [2][63]. A randomized trial in 120 patients with arrested PTL found that activity restriction (including pelvic rest and reduced work) did not reduce sPTB [64]. ACOG advises discontinuing exercise for warning symptoms such as regular contractions, vaginal bleeding, abdominal pain, fluid leakage, dyspnea before exertion, dizziness, headache, chest pain, muscle weakness, or calf pain [63].

Putting It All Together

Optimal sPTL management blends accurate risk recognition with targeted, time-bound therapy. High-risk presentations prompt corticosteroids, short-course tocolysis (unless contraindicated) to buy time for fetal benefit and transfer logistics, magnesium sulfate at early gestations for neuroprotection, and GBS prophylaxis where indicated. Choices among tocolytics reflect gestational age, maternal comorbidities, and side-effect profiles: indomethacin before 32 weeks for inflammatory-driven sPTL with strict time limits; nifedipine beyond 30–32 weeks for an effective, well-tolerated option; β2-agonists as second line; atosiban where available; and magnesium primarily for neuroprotection with selective tocolytic use. Institutional protocols should harmonize periviable care thresholds, standardize steroid timing and rescue-dose criteria, embed contraindications and reassessment triggers for tocolysis, and ensure neonatal readiness. Finally, as many symptomatic patients will not deliver imminently, applying these tools judiciously avoids over-treatment and ensures that those most likely to benefit receive time-sensitive interventions that meaningfully improve neonatal outcomes [1][2][33][34][35][36][37][38][39][40][41].

Differential Diagnosis:

The evaluation of a pregnant patient presenting with lower abdominal, pelvic, or back pain requires a careful and systematic approach, as multiple obstetric and non-obstetric conditions can mimic spontaneous preterm labor (sPTL). Distinguishing true preterm labor from these entities is crucial for preventing unnecessary interventions while ensuring timely management when delivery risk is genuine. Spontaneous Preterm Labor (sPTL) presents with regular, painful uterine contractions that lead to progressive cervical change—either dilation, effacement, or both. Contractions are typically rhythmic and associated with pelvic pressure or lower back pain. Objective confirmation of cervical change remains the hallmark of diagnosis. Braxton-Hicks contractions, or "false labor," are irregular, non-progressive uterine contractions that typically occur in the second and third trimesters. They are often relieved by rest, hydration, or changes in position and do not lead to cervical dilation or effacement. Monitoring contraction frequency and assessing cervical status over time helps differentiate these from true labor. Musculoskeletal or round ligament pain results from the physiologic stretching of uterine and pelvic ligaments as pregnancy advances. This pain is often sharp, positional, and transient, localized to the groin or lower abdomen, and unrelated to uterine contractions. Urinary tract infection (UTI) can mimic PTL due to irritative bladder symptoms and referred lower abdominal pain. Pyelonephritis may also trigger uterine irritability and, in severe cases, precipitate true preterm contractions. Urinalysis and culture are essential in any evaluation of suspected PTL. Gastrointestinal disorders, including constipation, gastroenteritis, and irritable bowel syndrome, may cause abdominal cramping or discomfort resembling contractions. A thorough dietary and bowel history aids in differentiation. Placental abruption should be suspected when abdominal pain is accompanied by vaginal bleeding, uterine tenderness, or abnormal fetal heart patterns. This obstetric emergency demands immediate evaluation. Uterine rupture, though rare before labor or in unscarred uteri, may present with sudden severe pain, fetal distress, or hemodynamic instability, particularly in patients with prior uterine surgery. Ultimately, accurate diagnosis relies on combining history, physical examination—including contraction monitoring and cervical assessment—and targeted testing to exclude mimics while promptly identifying true sPTL requiring intervention.

Conclusion:

In conclusion, the management of spontaneous preterm labor is a complex clinical challenge that demands an interdisciplinary and evidence-based approach. Its multifactorial nature, encompassing infectious, inflammatory, vascular, and mechanical pathways, necessitates a sophisticated diagnostic process to distinguish true labor from mimics and accurately stratify short-term delivery risk. The cornerstone of effective management lies in this precise risk assessment, which guides the judicious use of time-sensitive interventions. The administration of antenatal corticosteroids to accelerate fetal lung maturity and magnesium sulfate for fetal neuroprotection before early preterm birth are among the most impactful strategies, significantly reducing neonatal morbidity and mortality. Ultimately, optimizing outcomes requires a coordinated effort across maternal-fetal medicine, nursing, neonatology, and emergency care. This collaboration ensures that patients at genuine risk receive prompt, targeted therapy—including tocolysis to gain a critical 48-hour window and transfer to a tertiary care center—while those at low risk are spared unnecessary interventions. By integrating a deep understanding of PTL's pathophysiology with rigorous clinical evaluation and standardized, gestational age-based protocols, healthcare teams can effectively mitigate the adverse consequences of prematurity and improve long-term neonatal health.

References:

1. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. Practice Bulletin No. 171: Management of Preterm Labor. Obstetrics and gynecology. 2016 Oct:128(4):e155-64. doi: 10.1097/AOG.0000000000001711.
2. Dagklis T, Akolekar R, Villalain C, Tsakiridis I, Kesrouani A, Tekay A, Plasencia W, Wellmann S, Kusuda S, Jekova N, Prefumo F, Volpe N, Chaveeva P, Allegaert K, Khalil A, Sen C. Management of preterm labor: Clinical practice guideline and recommendation by the WAPM-World Association of Perinatal Medicine and the PMF-Perinatal Medicine Foundation. European journal of obstetrics, gynecology, and reproductive biology. 2023 Dec:291():196-205. doi: 10.1016/j.ejogrb.2023.10.013.
3. Waks AB, Martinez-King LC, Santiago G, Laurent LC, Jacobs MB. Developing a risk profile for spontaneous preterm birth and short interval to delivery among patients with threatened preterm labor. American journal of obstetrics & gynecology MFM. 2022 Nov:4(6):100727. doi: 10.1016/j.ajogmf.2022.100727.
4. Dagklis T, Sen C, Tsakiridis I, Villalaín C, Allegaert K, Wellmann S, Kusuda S, Serra B, Sanchez Luna M, Huertas E, Volpe N, Ayala R, Jekova N, Grunebaum A, Stanojevic M. The use of antenatal corticosteroids for fetal maturation: clinical practice guideline by the WAPM-World Association of Perinatal Medicine and the PMF-Perinatal Medicine foundation. Journal of perinatal medicine. 2022 May 25:50(4):375-385. doi: 10.1515/jpm-2022-0066.
5. Hoffman MK. Prediction and Prevention of Spontaneous Preterm Birth: ACOG Practice Bulletin, Number 234. Obstetrics and gynecology. 2021 Dec 1:138(6):945-946. doi: 10.1097/AOG.0000000000004612.
6. Hall M, Valencia CM, Soma-Pillay P, Luyt K, Jacobsson B, Shennan A, FIGO Preterm Birth Committee. Effective and simple interventions to improve outcomes for preterm infants worldwide: The FIGO PremPrep-5 initiative. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2024 Jun:165(3):929-935. doi: 10.1002/ijgo.15269.
7. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet (London, England). 2008 Jan 5:371(9606):75-84. doi: 10.1016/S0140-6736(08)60074-4. Epub
8. Romero R, Dey SK, Fisher SJ. Preterm labor: one syndrome, many causes. Science (New York, N.Y.). 2014 Aug 15:345(6198):760-5. doi: 10.1126/science.1251816. Epub 2014 Aug 14
9. Preston M, Hall M, Shennan A, Story L. The role of placental insufficiency in spontaneous preterm birth: A literature review. European journal of obstetrics, gynecology, and reproductive biology. 2024 Apr:295():136-142. doi: 10.1016/j.ejogrb.2024.02.020.
10. Sen C. Preterm labor and preterm birth. Journal of perinatal medicine. 2017 Nov 27:45(8):911-913. doi: 10.1515/jpm-2017-0298.
11. Romero R, Espinoza J, Kusanovic JP, Gotsch F, Hassan S, Erez O, Chaiworapongsa T, Mazor M. The preterm parturition syndrome. BJOG : an international journal of obstetrics and gynaecology. 2006 Dec:113 Suppl 3(Suppl 3):17-42
12. O'Hara S, Zelesco M, Sun Z. Cervical length for predicting preterm birth and a comparison of ultrasonic measurement techniques. Australasian journal of ultrasound in medicine. 2013 Aug:16(3):124-134. doi: 10.1002/j.2205-0140.2013.tb00100.x. Epub 2015 Dec 31
13. Ohuma EO, Moller AB, Bradley E, Chakwera S, Hussain-Alkhateeb L, Lewin A, Okwaraji YB, Mahanani WR, Johansson EW, Lavin T, Fernandez DE, Domínguez GG, de Costa A, Cresswell JA, Krasevec J, Lawn JE, Blencowe H, Requejo J, Moran AC. National, regional, and global estimates of preterm birth in 2020, with trends from 2010: a systematic analysis. Lancet (London, England). 2023 Oct 7:402(10409):1261-1271. doi: 10.1016/S0140-6736(23)00878-4. Epub
14. Mensah NA, Fassett MJ, Shi JM, Kawatkar AA, Xie F, Chiu VY, Yeh M, Avila CC, Khadka N, Sacks DA, Getahun D. Examining recent trends in spontaneous and iatrogenic preterm birth across race and ethnicity in a large managed care population. American journal of obstetrics and gynecology. 2023 Jun:228(6):736.e1-736.e15. doi: 10.1016/j.ajog.2022.11.1288.
15. Oner C, Schatz F, Kizilay G, Murk W, Buchwalder LF, Kayisli UA, Arici A, Lockwood CJ. Progestin-inflammatory cytokine interactions affect matrix metalloproteinase-1 and -3 expression in term decidual cells: implications for treatment of chorioamnionitis-induced preterm delivery. The Journal of clinical endocrinology and metabolism. 2008 Jan:93(1):252
16. Gomez-Lopez N, Galaz J, Miller D, Farias-Jofre M, Liu Z, Arenas-Hernandez M, Garcia-Flores V, Shaffer Z, Greenberg JM, Theis KR, Romero R. The immunobiology of preterm labor and birth: intra-amniotic inflammation or breakdown of

maternal-fetal homeostasis. Reproduction (Cambridge, England). 2022 Jun 20:164(2):R11-R45. doi: 10.1530/REP-22-0046.
17. DeFranco EA, Lewis DF, Odibo AO. Improving the screening accuracy for preterm labor: is the combination of fetal fibronectin and cervical length in symptomatic patients a useful predictor of preterm birth? A systematic review. American journal of obstetrics and gynecology. 2013 Mar:208(3):233.e1-6. doi: 10.1016/j.ajog.2012.12.015.
18. Creswell L, Rolnik DL, Lindow SW, O'Gorman N. Preterm Birth: Screening and Prediction. International journal of women's health. 2023:15():1981-1997. doi: 10.2147/IJWH.S436624. Epub 2023 Dec 21
19. Yılmaz Semerci S, Yücel B, Erbas IM, Gunkaya OS, Talmac M, Çetinkaya M. The utility of amniotic fluid pH and electrolytes for prediction of neonatal respiratory disorders. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians. 2020 Jan:33(2):253-257. doi: 10.1080/14767058.2018.1488961. Epub 2018 Jul 22
20. Riedewald S, Kreutzmann IM, Heinze T, Saling E. Vaginal and cervical pH in normal pregnancy and pregnancy complicated by preterm labor. Journal of perinatal medicine. 1990:18(3):181-6
21. Cousins LM, Smok DP, Lovett SM, Poeltler DM. AmniSure placental alpha microglobulin-1 rapid immunoassay versus standard diagnostic methods for detection of rupture of membranes. American journal of perinatology. 2005 Aug:22(6):317-20
22. Lee SE, Park JS, Norwitz ER, Kim KW, Park HS, Jun JK. Measurement of placental alpha-microglobulin-1 in cervicovaginal discharge to diagnose rupture of membranes. Obstetrics and gynecology. 2007 Mar:109(3):634-40
23. Thomasino T, Levi C, Draper M, Neubert AG. Diagnosing rupture of membranes using combination monoclonal/polyclonal immunologic protein detection. The Journal of reproductive medicine. 2013 May-Jun:58(5-6):187-94
24. . Prevention of Group B Streptococcal Early-Onset Disease in Newborns: ACOG Committee Opinion, Number 797. Obstetrics and gynecology. 2020 Feb:135(2):e51-e72. doi: 10.1097/AOG.0000000000003668.
25. Prodan N, Wagner P, Sonek J, Abele H, Hoopmann M, Kagan KO. Single and repeat cervical-length measurement in twin gestation with threatened preterm labor. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2020 Apr:55(4):496-501. doi: 10.1002/uog.20306.
26. Gomez R, Romero R, Medina L, Nien JK, Chaiworapongsa T, Carstens M, González R, Espinoza J, Iams JD, Edwin S, Rojas I. Cervicovaginal fibronectin improves the prediction of preterm delivery based on sonographic cervical length in patients with preterm uterine contractions and intact membranes. American journal of obstetrics and gynecology. 2005 Feb:192(2):350-9
27. McLaren JS, Hezelgrave NL, Ayubi H, Seed PT, Shennan AH. Prediction of spontaneous preterm birth using quantitative fetal fibronectin after recent sexual intercourse. American journal of obstetrics and gynecology. 2015 Jan:212(1):89.e1-5. doi: 10.1016/j.ajog.2014.06.055. Epub 2014 Jun 30
28. Son M, Miller ES. Predicting preterm birth: Cervical length and fetal fibronectin. Seminars in perinatology. 2017 Dec:41(8):445-451. doi: 10.1053/j.semperi.2017.08.002. Epub 2017 Sep 19
29. Ness A, Visintine J, Ricci E, Berghella V. Does knowledge of cervical length and fetal fibronectin affect management of women with threatened preterm labor? A randomized trial. American journal of obstetrics and gynecology. 2007 Oct:197(4):426.e1-7
30. van Baaren GJ, Vis JY, Wilms FF, Oudijk MA, Kwee A, Porath MM, Oei G, Scheepers HCJ, Spaanderman MEA, Bloemenkamp KWM, Haak MC, Bolte AC, Bax CJ, Cornette JMJ, Duvekot JJ, Nij Bijvanck BWA, van Eyck J, Franssen MTM, Sollie KM, Vandenbussche FPHA, Woiski M, Grobman WA, van der Post JAM, Bossuyt PMM, Opmeer BC, Mol BWJ. Predictive value of cervical length measurement and fibronectin testing in threatened preterm labor. Obstetrics and gynecology. 2014 Jun:123(6):1185-1192. doi: 10.1097/AOG.0000000000000229. Epub
31. Abbott DS, Radford SK, Seed PT, Tribe RM, Shennan AH. Evaluation of a quantitative fetal fibronectin test for spontaneous preterm birth in symptomatic women. American journal of obstetrics and gynecology. 2013 Feb:208(2):122.e1-6. doi: 10.1016/j.ajog.2012.10.890. Epub 2012 Nov 16
32. Nikolova T, Uotila J, Nikolova N, Bolotskikh VM, Borisova VY, Di Renzo GC. Prediction of spontaneous preterm delivery in women presenting with premature labor: a comparison of placenta alpha microglobulin-1, phosphorylated insulin-like growth factor binding protein-1, and cervical length. American journal of obstetrics and gynecology. 2018 Dec:219(6):610.e1-610.e9. doi: 10.1016/j.ajog.2018.09.016.

33. Dayal S, Jenkins SM, Hong PL. Preterm and Term Prelabor Rupture of Membranes (PPROM and PROM). StatPearls. 2025 Jan
34. Gyamfi-Bannerman C, Thom EA. Antenatal Betamethasone for Women at Risk for Late Preterm Delivery. The New England journal of medicine. 2016 Aug 4:375(5):486-7. doi: 10.1056/NEJMc1605902.
35. Deshmukh US, Lundsberg LS, Pettker CM, Rouse DJ, Reddy UM. Neonatal outcomes by delivery indication after administration of antenatal late preterm corticosteroids. AJOG global reports. 2022 Nov:2(4):100097. doi: 10.1016/j.xagr.2022.100097.
36. Kamath-Rayne BD, Rozance PJ, Goldenberg RL, Jobe AH. Antenatal corticosteroids beyond 34 weeks gestation: What do we do now? American journal of obstetrics and gynecology. 2016 Oct:215(4):423-30. doi: 10.1016/j.ajog.2016.06.023. Epub 2016 Jun 21
37. Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org, Reddy UM, Deshmukh U, Dude A, Harper L, Osmundson SS. Society for Maternal-Fetal Medicine Consult Series #58: Use of antenatal corticosteroids for individuals at risk for late preterm delivery: Replaces SMFM Statement #4, Implementation of the use of antenatal corticosteroids in the late preterm birth period in women at risk for preterm delivery, August 2016. American journal of obstetrics and gynecology. 2021 Nov:225(5):B36-B42. doi: 10.1016/j.ajog.2021.07.023. Epub 2021 Aug 5
38. Committee on Obstetric Practice. Committee Opinion No. 713: Antenatal Corticosteroid Therapy for Fetal Maturation. Obstetrics and gynecology. 2017 Aug:130(2):e102-e109. doi: 10.1097/AOG.0000000000002237.
39. Stock SJ, Thomson AJ, Papworth S, Royal College of Obstetricians and Gynaecologists. Antenatal corticosteroids to reduce neonatal morbidity and mortality: Green-top Guideline No. 74. BJOG : an international journal of obstetrics and gynaecology. 2022 Jul:129(8):e35-e60. doi: 10.1111/1471-0528.17027.
40. Liauw J, Foggin H, Socha P, Crane J, Joseph KS, Burrows J, Lacaze-Masmonteil T, Jain V, Boutin A, Hutcheon J. Technical Update No. 439: Antenatal Corticosteroids at Late Preterm Gestation. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC. 2023 Jun:45(6):445-457.e2. doi: 10.1016/j.jogc.2022.12.006. Epub 2022 Dec 23
41. Vogel JP, Ramson J, Darmstadt GL, Qureshi ZP, Chou D, Bahl R, Oladapo OT. Updated WHO recommendations on antenatal corticosteroids and tocolytic therapy for improving preterm birth outcomes. The Lancet. Global health. 2022 Dec:10(12):e1707-e1708. doi: 10.1016/S2214-109X(22)00434-X.
42. Crowther CA, Haslam RR, Hiller JE, Doyle LW, Robinson JS, Australasian Collaborative Trial of Repeat Doses of Steroids (ACTORDS) Study Group. Neonatal respiratory distress syndrome after repeat exposure to antenatal corticosteroids: a randomised controlled trial. Lancet (London, England). 2006 Jun 10:367(9526):1913-
43. Wilson A, Hodgetts-Morton VA, Marson EJ, Markland AD, Larkai E, Papadopoulou A, Coomarasamy A, Tobias A, Chou D, Oladapo OT, Price MJ, Morris K, Gallos ID. Tocolytics for delaying preterm birth: a network meta-analysis (0924). The Cochrane database of systematic reviews. 2022 Aug 10:8(8):CD014978. doi: 10.1002/14651858.CD014978.pub2. Epub 2022 Aug 10
44. Haas DM, Imperiale TF, Kirkpatrick PR, Klein RW, Zollinger TW, Golichowski AM. Tocolytic therapy: a meta-analysis and decision analysis. Obstetrics and gynecology. 2009 Mar:113(3):585-594. doi: 10.1097/AOG.0b013e318199924a.
45. Conde-Agudelo A, Romero R, Kusanovic JP. Nifedipine in the management of preterm labor: a systematic review and metaanalysis. American journal of obstetrics and gynecology. 2011 Feb:204(2):134.e1-20. doi: 10.1016/j.ajog.2010.11.038.
46. Flenady V, Wojcieszek AM, Papatsonis DN, Stock OM, Murray L, Jardine LA, Carbonne B. Calcium channel blockers for inhibiting preterm labour and birth. The Cochrane database of systematic reviews. 2014 Jun 5:2014(6):CD002255. doi: 10.1002/14651858.CD002255.pub2. Epub 2014 Jun 5
47. Xiong Z, Pei S, Zhu Z. Four kinds of tocolytic therapy for preterm delivery: Systematic review and network meta-analysis. Journal of clinical pharmacy and therapeutics. 2022 Jul:47(7):1036-1048. doi: 10.1111/jcpt.13641.
48. Vermillion ST, Scardo JA, Lashus AG, Wiles HB. The effect of indomethacin tocolysis on fetal ductus arteriosus constriction with advancing gestational age. American journal of obstetrics and gynecology. 1997 Aug:177(2):256-9; discussion 259-61
49. Savage AH, Anderson BL, Simhan HN. The safety of prolonged indomethacin therapy. American journal of perinatology. 2007 Apr:24(4):207-13
50. Hammers AL, Sanchez-Ramos L, Kaunitz AM. Antenatal exposure to indomethacin increases the risk of severe intraventricular hemorrhage, necrotizing enterocolitis, and periventricular leukomalacia: a systematic review with metaanalysis. American journal of obstetrics and

gynecology. 2015 Apr:212(4):505.e1-13. doi: 10.1016/j.ajog.2014.10.1091. Epub 2014 Oct 30

51. Haas DM, Caldwell DM, Kirkpatrick P, McIntosh JJ, Welton NJ. Tocolytic therapy for preterm delivery: systematic review and network meta-analysis. BMJ (Clinical research ed.). 2012 Oct 9:345():e6226. doi: 10.1136/bmj.e6226.
52. van Vliet EOG, Nijman TAJ, Schuit E, Heida KY, Opmeer BC, Kok M, Gyselaers W, Porath MM, Woiski M, Bax CJ, Bloemenkamp KWM, Scheepers HCJ, Jacquemyn Y, Beek EV, Duvekot JJ, Franssen MTM, Papatsonis DN, Kok JH, van der Post JAM, Franx A, Mol BW, Oudijk MA. Nifedipine versus atosiban for threatened preterm birth (APOSTEL III): a multicentre, randomised controlled trial. Lancet (London, England). 2016 May 21:387(10033):2117-2124. doi: 10.1016/S0140-6736(16)00548-1.
53. Duckitt K, Thornton S, O'Donovan OP, Dowswell T. Nitric oxide donors for treating preterm labour. The Cochrane database of systematic reviews. 2014 May 8:2014(5):CD002860. doi: 10.1002/14651858.CD002860.pub2.
54. Rouse DJ, Hirtz DG, Thom E, Varner MW, Spong CY, Mercer BM, Iams JD, Wapner RJ, Sorokin Y, Alexander JM, Harper M, Thorp JM Jr, Ramin SM, Malone FD, Carpenter M, Miodovnik M, Moawad A, O'Sullivan MJ, Peaceman AM, Hankins GD, Langer O, Caritis SN, Roberts JM, Eunice Kennedy Shriver NICHD Maternal-Fetal Medicine Units Network. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. The New England journal of medicine. 2008 Aug 28:359(9):895-905. doi: 10.1056/NEJMoa0801187. Epub
55. Shepherd ES, Goldsmith S, Doyle LW, Middleton P, Marret S, Rouse DJ, Pryde P, Wolf HT, Crowther CA. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. The Cochrane database of systematic reviews. 2024 May 10:5(5):CD004661. doi: 10.1002/14651858.CD004661.pub4.
56. Conde-Agudelo A, Romero R. Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and metaanalysis. American journal of obstetrics and gynecology. 2009 Jun:200(6):595-609. doi: 10.1016/j.ajog.2009.04.005.
57. WHO Recommendations on Interventions to Improve Preterm Birth Outcomes. 2015:(): Prevention of Early-onset Neonatal Group B Streptococcal Disease: Green-top Guideline No. 36. BJOG : an international journal of obstetrics and gynaecology. 2017 Nov:124(12):e280-e305. doi: 10.1111/1471-0528.14821. Epub 2017 Sep 13
58. Fogarty M, Osborn DA, Askie L, Seidler AL, Hunter K, Lui K, Simes J, Tarnow-Mordi W. Delayed vs early umbilical cord clamping for preterm infants: a systematic review and meta-analysis. American journal of obstetrics and gynecology. 2018 Jan:218(1):1-18. doi: 10.1016/j.ajog.2017.10.231. Epub 2017 Oct 30
59. Seidler AL, Aberoumand M, Hunter KE, Barba A, Libesman S, Williams JG, Shrestha N, Aagerup J, Sotiropoulos JX, Montgomery AA, Gyte GML, Duley L, Askie LM, iCOMP Collaborators. Deferred cord clamping, cord milking, and immediate cord clamping at preterm birth: a systematic review and individual participant data meta-analysis. Lancet (London, England). 2023 Dec 9:402(10418):2209-2222. doi: 10.1016/S0140-6736(23)02468-6. Epub 2023 Nov 14
60. Chartrand L, Barrington KJ, Dodin P, Villeneuve A. Delayed cord clamping in preterm twin infants: a systematic review and meta-analysis. American journal of obstetrics and gynecology. 2024 Oct 28:():. pii: S0002-9378(24)01085-8. doi: 10.1016/j.ajog.2024.10.024. Epub 2024 Oct 28
61. Chaudhary P, Priyadarshi M, Singh P, Chaurasia S, Chaturvedi J, Basu S. Effects of delayed cord clamping at different time intervals in late preterm and term neonates: a randomized controlled trial. European journal of pediatrics. 2023 Aug:182(8):3701-3711. doi: 10.1007/s00431-023-05053-6.
62. Mota P, Bø K. ACOG Committee Opinion No. 804: Physical Activity and Exercise During Pregnancy and the Postpartum Period. Obstetrics and gynecology. 2021 Feb 1:137(2):376. doi: 10.1097/AOG.0000000000004267. Epub
63. Saccone G, Della Corte L, Cuomo L, Reppuccia S, Murolo C, Napoli FD, Locci M, Bifulco G. Activity restriction for women with arrested preterm labor: a randomized controlled trial. American journal of obstetrics & gynecology MFM. 2023 Aug:5(8):100954. doi: 10.1016/j.ajogmf.2023.100954. Epub 2023 Apr 18
64. Fuchs IB, Henrich W, Osthues K, Dudenhausen JW. Sonographic cervical length in singleton pregnancies with intact membranes presenting with threatened preterm labor. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2004 Oct:24(5):554-7
65. Crump C, Sundquist J, Sundquist K. Adverse Pregnancy Outcomes and Long-Term Mortality in Women. JAMA internal medicine. 2024 Jun 1:184(6):631-640. doi: 10.1001/jamainternmed.2024.0276. Epub
66. Bell EF, Hintz SR, Hansen NI, Bann CM, Wyckoff MH, DeMauro SB, Walsh MC, Vohr BR, Stoll BJ, Carlo WA, Van Meurs KP, Rysavy MA, Patel RM, Merhar SL, Sánchez PJ, Laptook AR, Hibbs AM, Cotten CM, D'Angio CT, Winter S,

Fuller J, Das A, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Mortality, In-Hospital Morbidity, Care Practices, and 2-Year Outcomes for Extremely Preterm Infants in the US, 2013-2018. JAMA. 2022 Jan 18:327(3):248-263. doi: 10.1001/jama.2021.23580. Epub

67. Ward RM, Beachy JC. Neonatal complications following preterm birth. BJOG : an international journal of obstetrics and gynaecology. 2003 Apr:110
68. Moore T, Hennessy EM, Myles J, Johnson SJ, Draper ES, Costeloe KL, Marlow N. Neurological and developmental outcome in extremely preterm children born in England in 1995 and 2006: the EPICure studies. BMJ (Clinical research ed.). 2012 Dec 4:345():e7961. doi: 10.1136/bmj.e7961. Epub 2012 Dec 4
69. Nelson DB, Lafferty A, Venkatraman C, McDonald JG, Eckert KM, McIntire DD, Spong CY. Association of Vaginal Progesterone Treatment With Prevention of Recurrent Preterm Birth. JAMA network open. 2022 Oct 3:5(10):e2237600. doi: 10.1001/jamanetworkopen.2022.37600. Epub 2022 Oct 3
70. Conde-Agudelo A, Romero R. Does vaginal progesterone prevent recurrent preterm birth in women with a singleton gestation and a history of spontaneous preterm birth? Evidence from a systematic review and meta-analysis. American journal of obstetrics and gynecology. 2022 Sep:227(3):440-461.e2. doi: 10.1016/j.ajog.2022.04.023. Epub 2022 Apr 20